OVVI Diagnostics is focusing on Women’s health.

We are building a Point-of-Care testing solution with a panel of tests specifically to address Women’s health issues.

OVVI Diagnostics is focusing on Women’s health.

We are first targeting tests performed by Obstetricians and Gynecologists (OB/GYN).

Our first tests under development are for improving the management of Post-Partum Hemorrhage, to help the diagnosis and prognosis of pre-eclampsia and the monitoring of fertility.

We are first targeting tests performed by Obstetricians and Gynecologists (OB/GYN).

 

Presentation of our solution

OVVI Diagnostics is building a Point-of-Care (POC) testing solution with a panel of tests specifically to address Women’s health issues.

 

Our solution will cover the full spectrum of POC testing needs of women throughout their adult life.

 

Firstly by targeting tests performed by OB/GYN’s either during consultations or in hospital.

 

Secondly with self-testing by the patient or by a nurse at home with results automatically transmitted to the physician.

Advantages of our Solution

  • Developing a panel of tests for Women's health
    We are seeking to cover a panel of tests throughout the life of women to respond to OB/GYN needs.
  • Comparable to core lab assays
    Thanks to our magnetic detection technology and to high-sensitive lateral flow technology, our Point-of-Care tests are comparable to core lab assays.
  • Fast result at the Point-of Care
    By providing a result in less than 20 minutes, the physician can take a quick decision with the patient near at hand.
  • Sample flexibility
    From one drop of blood (< 50 µl) or whole blood, our solution is quick and easy to use.
OVVI Diagnostics

Our tests under development

1Post-Partum hemorrhage (PPH)

"Post-Partum hemorrhage (PPH) remains the leading cause of maternal mortality worldwide, responsible for about one-quarter of maternal deaths…"
"Fibrinogen is a critical factor for hemostasis involved in the architecture of the clot and an important predictor of the severity of PPH…"
Ovvi Diagnostics is developing a Point-of-Care test for fibrinogen quantification in blood, providing a result comparable to core laboratories in few minutes to improve the management of PPH..

2Pre-eclampsia (PE)

"Pre-eclampsia (PE) concerns 2–8% of pregnancies and remains a leading cause of maternal and perinatal mortality and morbidity..."
"During the first trimester of pregnancy, the combination of PlGF with clinical, biophysical and biological factors improve the detection rate of PE. During the 2nd and 3rd trimesters, these biomarkers proved to be helpful for short-term prediction, diagnosis and prognosis of PE…"
Ovvi Diagnostics is developing a Point-of-Care solution for PE biomarker testing, giving precise quantitative results within minutes from a simple fingerprick.

3Infertility

"In vitro fertilization (IVF) is a series of procedures used to treat infertility. It is the most frequent and effective form of assisted reproductive technology (ART). Over 470,000 IVF cycles were recorded in Europe in 2013..."
"Female hormone blood testing is one of the most important tools for the physician to diagnose infertility, assess ovulation and ovarian reserve, and monitor IVF..."
Ovvi Diagnostics is developing a Point-of-Care solution for hormone blood testing with lab-quality results obtained in a few minutes directly from a fingerprick.

OVVI Diagnostics

Latest News

Creation of OVVI Diagnostics in Liege, Belgium.

7 Jul 2020

Creation of OVVI Diagnostics in Liege, Belgium.

OVVI Diagnostics takes over magnetic detection technology from Magnisense.

7 Jul 2020

OVVI Diagnostics takes over magnetic detection technology from Magnisense.

The first Point-of-Care testing system exclusively focused on Women’s health.

 

Contact us

Thank you to recopy the code below: